Subscribe to RSS
Similarities and Differences in Distortion-Product Otoacoustic Emissions Among Four FDA-Approved Devices
Similarities and differences in distortion-product otoacoustic emissions (DPOAEs) among four Food and Drug Administration (FDA) approved devices were assessed quantitatively. DPOAEs were recorded from 42 adult subjects (84 ears) ranging in age from 19 to 40 years. All subjects had hearing thresholds of 20 dB HL or better for the test frequencies from 0.25 to 8.0 kHz and normal acoustic immittance findings. DPOAEs were collected in a quiet non-sound-treated room. DPOAE measurement parameters included an f2/f1 ratio of ~1.2, with f1 at 65 dB SPL (L1) and f2 at 55 dB SPL (L2). There were no significant differences in the mean emissions levels among the four devices. This investigation showed that validity criteria, pass criteria, and strategies for DPOAE measurements interact to produce varying pass and refer results. However, when DPOAEs are obtained with consistent validity criteria, pass criteria, and strategies for measurement, the results are remarkably consistent.
Abbreviations: ANOVA = analysis of variance, CNS = central nervous system, DPOAEs = distortion-product otoacoustic emissions, FDA = Food and Drug Administration, L = level, OAEs = otoacoustic emissions, SNR = signal-to-noise ratio
KeywordsDistortion-product otoacoustic emissions - otoacoustic emissions - outer hair cells - signal-to-noise ratio - universal hearing screening
Article published online:
04 March 2022
© 2001. American Academy of Audiology. This article is published by Thieme.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- Abdala C. (1996). Distortion product otoacoustic emission (2f -f2) amplitude as a function of f2/f1 frequency ratio and primary tone level separation in human adults and neonates. J Acoust Soc Am 100:3726-3740.
- Gorga MP, Norton SJ, Siniger YS, Cone-Wesson B, Folsom RC, Vohr BR, Widen JE, Neely ST. (2000). Identification of neonatal hearing impairment: distortion product otoacoustic emissions during perinatal period. Ear Hear 21:400-424.
- Harris F, Probst R. (1997). Otoacoustic emissions and audiometric outcomes. In: Robinette MS, Glattke TJ, ed. Otoacoustic Emissions: Clinical Applications. New York: Thieme Medical, 151-180.
- Hornsby B, Kelly T, Hall JW III. (1996). Normative data for five FDA-approved distortion product OAE system. Hear J 49:39-46.
- Joint Committee on Infant Hearing. (2000). Principles and guidelines for early hearing detection and intervention programs. Position statement. Am J Audiol 9:9-29.
- Kemp DT, Ryan S, Bray P. (1990). A guide to the effective use of otoacoustic emissions. Ear Hear 11:93-105.
- Lonsbury-Martin BL, McCoy MJ, Whitehead ML, Martin GK. (1993). Clinical testing of distortion-product otoacoustic emissions. Ear Hear 1:11-22.
- National Institutes of Health. (1993). Early identification of hearing impairment in infants and young children. Consensus statement. Washington, DC: Public Health Service.
- Popelka GR, Osterhammel PA, Nielsen LH, Rasmussen AN. (1993). Growth of distortion product otoacoustic emissions with primary-tone level in humans. Hear Res 71:12-22.
- Popelka GR, Karzon RK, Arjmand EM. (1995). Growth of the 2f1-f2 distortion product otoacoustic emission for low level stimuli in human neonates. Ear Hear 16:159-165.
- Popelka GR, Karzon RK, Clary RA. (1998). Identification of noise sources that influence distortion product otoacoustic emission measurements in human neonates. Ear Hear 19:319-328.
- Siegel JH. (1994). Ear canal standing waves and high-frequency sound calibration using otoacoustic emission probe. J Acoust Soc Am 95:2589-2597.
- Siegel JH. (1995). Cross-talk in otoacoustic emission probes. Ear Hear 16:150-158.
- Stach BA, Santilli CL. (1998). Technology in newborn hearing screening. Semin Hear 19:247-262.
- Vinck MB, Del Vel ED, Xu ZM, Van Cauwenberge PB. (1996). Distortion product otoacoustic emissions: a normative study. Audiology 35:231-245.